StockNews.AISignal intelligence
Eton Pharmaceuticals, Inc. · NASDAQ · Healthcare
Browse public ETON signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Eton Pharmaceuticals has announced the FDA approval of DESMODA, an oral solution for central diabetes insipidus, set to launch on March 9, 2026. This innovative medication introduces precise dosing for patients and is projected to generate peak sales between $30-50 million annually, marking a significant growth opportunity for Eton in the rare disease market.
View signal analysisFDA approved Eton's Khindivi for pediatric adrenal insufficiency treatment. Khindivi offers an easy-to-use hydrocortisone oral solution for patients aged 5+. Eton predicts revenues of $28 million by 2030, growing from $3 million in 2025. Analyst maintains Buy rating, raising price target for ETON stock to $35.
View signal analysis